Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation

被引:0
|
作者
Gregory S. Sawicki
Michael W. Konstan
Edward F. McKone
Richard B. Moss
Barry Lubarsky
Ellison Suthoff
Stefanie J. Millar
David J. Pasta
Nicole Mayer-Hamblett
Christopher H. Goss
Wayne J. Morgan
Margaret E. Duncan
Yoojung Yang
机构
[1] Harvard Medical School,Boston Children’s Hospital
[2] Case Western Reserve University School of Medicine,undefined
[3] Rainbow Babies and Children’s Hospital,undefined
[4] St Vincent’s University Hospital,undefined
[5] Stanford University,undefined
[6] Vertex Pharmaceuticals Incorporated,undefined
[7] Formerly of ICON Clinical Research,undefined
[8] Seattle Children’s Hospital,undefined
[9] University of Washington,undefined
[10] University of Arizona,undefined
来源
Pulmonary Therapy | 2022年 / 8卷
关键词
Cystic fibrosis; Lung function; Lung function decline; Residual function;
D O I
暂无
中图分类号
学科分类号
摘要
In people with cystic fibrosis, lung function typically decreases over time and is linked to the severity of the disease. How fast lung function decreases (referred to as the rate of lung function decline) in cystic fibrosis depends on the specific mutations (changes) in the CFTR gene (which causes the disease). Lung function decline has been well studied in some mutation groups, but not many previous studies have looked at lung function decline in people with one copy of the F508del-CFTR mutation (which is the most common CFTR mutation and results in little to no functional CFTR protein) and another CFTR mutation called a residual function mutation (referred to as people with F/RF genotypes). We used data from the US Cystic Fibrosis Foundation Patient Registry (which collects information on the health of people in the USA who have cystic fibrosis), to look at the rate of lung function decline in people with F/RF genotypes. We found that people with cystic fibrosis who have F/RF genotypes experience lung function loss over time. We also found that this lung function loss occurred in people of all ages with F/RF genotypes. This finding supports the importance of early treatment to help prevent lung function loss in all people with cystic fibrosis, including people with F/RF genotypes.
引用
收藏
页码:385 / 395
页数:10
相关论文
共 50 条
  • [41] Lipidome Alterations Induced by Cystic Fibrosis, CFTR Mutation, and Lung Function
    Buzatto, Adriana Zardini
    Jabar, Mai Abdel
    Nizami, Imran
    Dasouki, Majed
    Li, Liang
    Rahman, Anas M. Abdel
    JOURNAL OF PROTEOME RESEARCH, 2021, 20 (01) : 549 - 564
  • [42] Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis
    De Boeck, K.
    Vermeulen, F.
    Wanyama, S.
    Thomas, M.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (05) : 1091 - 1095
  • [43] Reduced survival in adult cystic fibrosis despite attenuated lung function decline
    Keating, Claire
    Poor, Arrneen D.
    Liu, Xinhua
    Chiuzan, Codruta
    Backenroth, Daniel
    Zhang, Yuan
    DiMango, Emily
    JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (01) : 78 - 84
  • [44] A Tool for Predicting Risk of Future Lung Function Decline in Cystic Fibrosis Patients
    Wagener, J.
    VanDevanter, D.
    Pasta, D.
    Elkin, E.
    Jacobs, J.
    Morgan, W.
    Konstan, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [45] Risk factors for early lung function decline in young children with Cystic Fibrosis
    Balinotti, Juan
    Chang, Daniel
    Rodriguez, Viviana
    Lubovich, Silvina
    Zaragoza, Silvina
    Escobar, Natalia
    Kofman, Carlos
    Perez, Lucia
    Ardiles, Victoria
    Teper, Alejandro
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [46] Pseudomonas aeruginosa type III secretion and lung function decline in cystic fibrosis
    Jain, M.
    Bar-Meir, M.
    King, J.
    Cullina, J.
    Potter, E.
    Powers, C.
    Seshadri, R.
    Yogev, R.
    McColley, S. A.
    PEDIATRIC PULMONOLOGY, 2007, : 316 - 317
  • [47] Predictors of lung function decline in stable non-cystic fibrosis bronchiectasis
    Ringshausen, Felix C.
    de Roux, Andres
    Pletz, Mathias W.
    Bange, Franz-Christoph
    Suhling, Hendrik
    Welte, Tobias
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [48] Effect of key pharmacological therapies on decline in lung function in adults with cystic fibrosis
    Berinaer, P.
    Chawla, S.
    Ahn, J.
    Tsou, J. A.
    Hidayat, L.
    Benitez, D.
    Rao, A. P.
    PEDIATRIC PULMONOLOGY, 2007, : 333 - 334
  • [49] MICROBIOTA COMPOSITION IN THE AIRWAYS OF CYSTIC FIBROSIS PATIENTS WITH A SEVERE DECLINE IN LUNG FUNCTION
    Bevivino, A.
    Paganin, P.
    Tuccio, V
    Chiancianesi, M.
    Bacci, G.
    Morelli, P.
    De Alessandri, A.
    Dolce, D.
    Taccetti, G.
    Dalmastri, C.
    Perrotta, G.
    Lucidi, V
    Fiscarelli, E., V
    Mengoni, A.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 316 - 316
  • [50] Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy
    Zhou, Grace C.
    Wang, Ziyun
    Palipana, Anushka K.
    Andrinopoulou, Eleni-Rosalina
    Miranda Afonso, Pedro
    Mcphail, Gary L.
    Siracusa, Christopher M.
    Gecili, Emrah
    Szczesniak, Rhonda D.
    RESPIRATORY RESEARCH, 2024, 25 (01)